<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01775358</url>
  </required_header>
  <id_info>
    <org_study_id>ALRN-100-01</org_study_id>
    <nct_id>NCT01775358</nct_id>
  </id_info>
  <brief_title>Phase 1 Safety Study of ALRN-5281 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety and Tolerability of ALRN-5281 Administered by Subcutaneous Injection in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aileron Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aileron Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of a single
      dose of ALRN-5281 administered by subcutaneous injection to healthy adult volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum IGF-1</measure>
    <time_frame>Predose, Day 1-Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum GH</measure>
    <time_frame>Predose, Day 1-Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of ALRN-5281</measure>
    <time_frame>Predose, Day 1- 0.5,1,2,3,4,6,8,10,12,14 and 16hr post dose , Day 2-Day11 and Day14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of ALRN-5281</measure>
    <time_frame>Predose, Day 1- 0.5,1,2,3,4,6,8,10,12,14 and 16hr post dose , Day 2-Day11 and Day14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]</measure>
    <time_frame>Pre Dose, Day1- 0.5,1,2,3,4,6,8,10,12,14 and 16h post dose, Day2- Day11 and Day 14</time_frame>
    <description>AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>ALRN-5281 0.015 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage-0.015 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALRN-5281 0.05 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage- 0.05 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALRN-5281 0.15 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage- 0.15 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 0.015 mg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosage- 0.015 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 0.05 mg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosage- 0.05 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 0.15 mg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosage - 0.15 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALRN-5281 0.015 mg/kg</intervention_name>
    <arm_group_label>ALRN-5281 0.015 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALRN-5281 0.05 mg/kg</intervention_name>
    <arm_group_label>ALRN-5281 0.05 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALRN-5281 0.15 mg/kg</intervention_name>
    <arm_group_label>ALRN-5281 0.15 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 0.015 mg/kg</intervention_name>
    <arm_group_label>Placebo 0.015 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 0.05mg/kg</intervention_name>
    <arm_group_label>Placebo 0.05 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 0.15mg/kg</intervention_name>
    <arm_group_label>Placebo 0.15 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female subjects aged 20 to 50 years, inclusive, at the time of
             informed consent.

          2. Subjects must be in good health as determined by the Investigator based on detailed
             medical history, physical examination, vital signs, clinical laboratory tests, ECGs
             and other screening evaluations.

          3. Ability to provide written informed consent and complying with all study requirements
             and restrictions.

          4. Is a non-smoker and non-tobacco user for a minimum of 6 months prior to screening

        Exclusion Criteria:

          1. History or current evidence of any clinically significant cardiac, endocrinologic,
             hematologic, hepatobiliary, immunologic, metabolic, urologic, pulmonary, neurologic,
             dermatologic, psychiatric, renal, or other major disease, as determined by the
             Investigator

          2. Previous treatment with any GH Releasing Hormone (GHRH) analog.

          3. Participation in another clinical trial or treatment with an investigational agent
             within 30 days or 5 half-lives, whichever is longer, prior to enrollment.

          4. History of cancer within the past five years (excluding non-melanoma skin cancer).

          5. History of alcohol or drug abuse or dependence within 12 months of screening as
             determined by the Investigator.

          6. Subjects with a body weight &gt; 120 kg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley D Vince, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vince and Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hubert C Chen, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Aileron Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vince and Associates Clinical Research, LLC</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2013</study_first_submitted>
  <study_first_submitted_qc>January 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2013</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

